Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company’s Special Meeting of Stockholders to be held on May 23, 2024
Guardion Health Sciences announced that its largest stockholder, Bradley Louis Radoff, who holds 18.92% of shares, has voted in favor of selling the Viactiv business and the Plan of Liquidation. The company estimates that the total distribution to stockholders from the liquidation will range between $9.00 and $11.00 per share, contingent on the approval of these proposals. The vote is scheduled for May 23, 2024. The sale agreement, valued at $17.2 million, was made with Doctor's Best Inc. and is contingent upon majority stockholder approval.
The company's board is unanimous in supporting these proposals, suggesting that not approving them could significantly risk the value of the company's shares. The transaction is expected to be completed by June 30, 2024, provided customary conditions are met. If the Plan of Liquidation is not approved, distributing the cash from the sale could be delayed due to ongoing public company expenses.
- Largest stockholder supports the proposals, indicating strong internal backing.
- Estimated liquidation distribution of $9.00 to $11.00 per share if approved, potentially beneficial for stockholders.
- Sale agreement valued at $17.2 million, providing significant cash influx.
- Unanimous support from the Board of Directors for the proposals.
- If proposals are not approved, there is substantial risk to the value of the company's shares.
- Failure to approve the Plan of Liquidation could delay cash distribution due to ongoing operational expenses.
- Non-approval of the Plan of Liquidation could threaten the company's Nasdaq listing.
- Actual distribution amounts may be lower than estimated due to unforeseen claims or expenses.
Insights
The sale of Activ Nutritional, LLC and subsequent Plan of Liquidation and Dissolution are significant financial events for Guardion Health Sciences. For shareholders, the proposed cash distribution of
However, shareholders should be aware of the inherent risks associated with liquidation. The final distribution amount depends on several contingencies and there's a possibility that the actual payout could be lower than estimated. The current estimates are based on numerous assumptions about liabilities, obligations and the ability to convert assets to cash efficiently.
From a broader perspective, the sale price of
In the short term, investors might experience volatility as the market reacts to the transaction's approval status and any new developments. For long-term investors, the liquidation might signal an end to their involvement with the company, requiring them to find new investment opportunities.
In summary, while the proposals offer a strategic exit for investors, they should carefully consider the associated risks and the finality of liquidation. The financial outcome heavily relies on factors detailed in the proxy statement, making it essential for investors to review this document thoroughly.
From a market perspective, the sale of the Viactiv brand and the subsequent plan of liquidation marks a significant pivot for Guardion Health Sciences. The decision to sell Viactiv and liquidate indicates that the company’s board did not see a sustainable path forward with its current business model. This can be seen as a prudent move to return value to shareholders in the face of challenging operational prospects.
The estimated distribution of
However, investors must consider the uncertainty surrounding the final distribution amount. The company's ability to convert its remaining assets into cash and resolve outstanding liabilities will be pivotal in determining the final payout. Market conditions, regulatory approvals and unforeseen claims could also affect the outcome.
In the broader market context, this liquidation could signal to other similar firms about the growing pressures within the clinical nutrition sector. For Guardion Health Sciences' competitors, this might create an opportunity to capture the market share left by Viactiv's exit.
In essence, while the proposed liquidation could lead to a favorable short-term return for shareholders, it underscores the need for due diligence and awareness of the potential risks and uncertainties involved in such a transition.
Company Estimates the Aggregate Potential Liquidating Distributions to Range from approximately
HOUSTON, TEXAS, May 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced today that Mr. Bradley Louis Radoff, who, together with his affiliates, holds approximately
Robert N. Weingarten, the Chairman of the Board of Directors, stated, “We appreciate the support of Mr. Radoff, especially since he is the single largest stockholder in the Company. We also hope that this additional estimate of the expected per share distribution of cash to our stockholders will assist stockholders who have not yet voted in their analysis of whether to support the proposals at our upcoming special meeting of stockholders. The Board of Directors remains unanimous in our strong support of all proposals described in our Proxy Statement.”
The timing and amount of the total distributions will depend upon a number of factors as described in the Proxy Statement, including, without limitation, the approval of the stockholders of both the sale of the Viactiv business and the Company’s Plan of Liquidation and Dissolution, the closing of the agreement to sell the Viactiv business on the terms contained in the Purchase Agreement (defined below) on or before June 30, 2024, the actual expenses incurred by the Company in connection with closing of the Purchase Agreement, the timing of the resolution of matters for which the Company has established a contingency reserve, the amount to be paid in satisfaction of such contingencies, the obligations satisfied and provisions made during the liquidation and winding-up process, the absence of any unexpected claims against the Company, as well as the Company’s ability to convert its remaining assets to cash on a timely basis. The Company has attempted to estimate reasonable reserves for such liabilities, obligations, expenses and claims against it. However, those estimates may be inaccurate, which may cause the amount the Company distributes to its stockholders to be substantially less than the amount it currently estimates. Stockholders are advised to carefully read the Proxy Statement.
Agreement to Sell Activ Nutritional, LLC
As previously announced, on January 30, 2024, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Doctor’s Best Inc., a Delaware corporation, for the sale of all of the outstanding equity interests of Activ Nutritional, LLC (“Activ”) for aggregate cash consideration of
The sale of Activ is conditioned upon receiving majority approval from the Company’s stockholders for this transaction. This transaction is the result of a broad review of strategic alternatives by the Company’s Board of Directors over the past year. The Board of Directors has determined that it is advisable and in the best interests of the Company and the Company’s stockholders to approve this transaction.
Potential Dissolution
In the event that the Company’s stockholders approve the transaction and the transaction closes, the Company would be left with minimal operations. The Board of Directors has additionally determined that it is in the best interests of the Company and its stockholders to approve a voluntary dissolution and liquidation of the Company pursuant to a Plan of Liquidation and Dissolution, which would authorize the Company to liquidate and dissolve in accordance with its terms. However, such decision would be subject to the Company’s ability to abandon or delay the Plan of Liquidation and Dissolution in the event that the Board of Directors determines that another transaction would be in the best interests of the Company’s stockholders.
Views and Recommendations of the Board of Directors
If both of these proposals are approved, stockholders would receive one or more liquidating cash distributions, which combined are expected to be between
If both of these proposals are not approved at the stockholders’ meeting on May 23, 2024, or any adjournment thereof, we believe that there is substantial risk to the value of the Company’s shares.
Accordingly, the Board of Directors unanimously and strongly recommends that stockholders vote FOR both proposals. The transaction remains on track for completion by June 30, 2024, subject to satisfaction or waiver of customary closing conditions.
If stockholders approve the sale of Activ but do not approve the Plan of Liquidation and Dissolution, the Company believes it will be more difficult for the Company to expeditiously distribute the maximal amount of cash from that sale to our stockholders, since the Company will need to retain cash to continue to fund the considerable on-going expenses it has as a public company and to operate its remaining ocular healthcare business while the Board of Directors considers strategic alternatives.
The Company’s common stock is listed and traded on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GHSI”. However, if the sale of Activ is approved but the Plan of Liquidation and Dissolution of the Company is not approved, we believe that maintaining our listing on Nasdaq will be difficult and uncertain.
Shares that are not voted are the same as a “NO” vote for each proposal, so every vote matters, regardless of how many shares a stockholder may own.
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. (Nasdaq: GHSI) is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. Information and risk factors with respect to Guardion and its business may be obtained in the Company’s filings with the SEC at www.sec.gov.
Additional Information and Where to Find it
In connection with the proposed sale of Activ and the Plan of Liquidation and Dissolution, the Company filed with the SEC a Definitive Proxy Statement and other relevant documents, including a form of proxy card, on April 8, 2024, which were mailed to the Company’s stockholders of record on April 5, 2024. Stockholders are urged to read the Definitive Proxy Statement and any other documents filed with the SEC in connection with the proposed sale of Activ and the Plan of Liquidation and Dissolution, or incorporated by reference in the Definitive Proxy Statement because they contain important information about such proposals. The Company’s filings with the SEC may be obtained without charge at www.sec.gov.
Participants in the Solicitation
The Company and its executive officers, directors, other members of management, and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of the Company is set forth in the Company’s definitive proxy statement.
Forward-Looking Statements
The matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.
These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the approval by the stockholders of the sale of Activ to Doctor’s Best Inc. and the Plan of Liquidation and Dissolution of the Company, the successful completion of the sale of Activ to Doctor’s Best Inc., the successful completion of the Company’s Plan of Liquidation and Dissolution if approved by the Company’s stockholders, the use of the proceeds received from the sale, the Company’s ability to continue to fund or wind-down its operations, including its ocular healthcare business, subsequent to the sale, any replacement and integration of new management team members if needed, the implementation of new financial, management, accounting and business software systems, supply chain disruptions, key retail and e-commerce disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.
Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about Guardion Health Sciences, Inc., Contact:
investors@guardionhealth.com
Phone: 1-800 873-5141 Ext 208
FAQ
What are the details of Guardion Health Sciences' upcoming stockholder vote on May 23, 2024?
What is the expected distribution per share if Guardion Health Sciences' proposals are approved?
Who is the buyer in Guardion Health Sciences' $17.2 million sale of Activ Nutritional?
What could happen if Guardion Health Sciences' Plan of Liquidation is not approved?
Why does Guardion Health Sciences recommend voting in favor of the proposals?
